Fireside Chat: RNAi as a Second Wave: From Validation to Expansion

Session details:

As an industry, we are no longer proving RNA-based medicines work - we are now exploring what they can become. Twenty years ago, RNA interference was an elegant biological hypothesis. Today, it’s an established therapeutic modality with regulatory approvals, global reach, and expanding clinical scope.

But the real opportunity lies in what comes next. We’re moving beyond rare, genetically defined diseases into broader populations. John Maraganore is the founder of Corsera Health and City Therapeutics, two new biotechs leveraging next-generation RNAi to solve important conditions like cardiovascular, ocular, hepatic and CNS diseases, where RNAi can enable durable, infrequent dosing and even preventive strategies.